Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-17-054555)

Filing Details

Accession Number:: 0001209191-17-054555
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-10-02 15:44:43
Reporting Period:: 2017-10-02

Accepted Time:: 2017-10-02 15:44:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1533040	Rxi Pharmaceuticals Corp	RXII	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1285648	Geert Cauwenbergh	C/O Rxi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA 01752	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	Acquisiton	2017-10-02	2,700	$0.44	135,283	No	4	P	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2017-10-02	200	$0.46	135,483	No	4	P	Direct
Common Stock, $0.0001 Par Value	Acquisiton	2017-10-02	7,100	$0.45	142,583	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.0001 Par Value	4,500	Indirect	By spouse
Common Stock, $0.0001 Par Value	450	Indirect	By son

Footnotes

Represents shares held by the Reporting Person's son. The Reporting Person disclaims beneficial ownership of such shares and this report shall not constitute an admission ofbeneficial ownership.